Why Statistical Evidence Is Not the Same as Clinical Impact
A covariate effect can be estimated precisely enough to differ from zero yet be too small to matter for exposure or dosing. Conversely, an estimate that is not statistically significant may still be compatible with an effect large enough to affect a clinical decision. Covariate assessment therefore has two distinct questions: how much evidence is there for an effect, and how large might its consequences be?
In an NLME model, a covariate effect describes how a model parameter differs across covariate values, according to the specified model. Its clinical implications are usually indirect: a change in a pharmacokinetic parameter may alter predicted exposure under a particular dose and regimen. That translation depends on the model and the clinical context; a parameter effect should not automatically be treated as a dosing recommendation.
For a large-sample Wald calculation, if the estimate is approximately normally distributed with standard error \(SE(\hat{\delta})\), a two-sided 95% confidence interval is
A Wald test of \(H_0:\delta=0\) uses \(z=\hat{\delta}/SE(\hat{\delta})\). The resulting p-value measures how incompatible the observed estimate, or a more extreme one, is with that null model under the test assumptions. It does not measure the probability that the null is true, nor does it quantify clinical importance. The interval is useful because it shows both the estimated direction and the range of effect sizes reasonably compatible with the data under the model and approximation.
Translate the Effect to a Relevant Outcome
The parameter scale alone may not make the clinical implications clear. A useful assessment begins with a prespecified covariate contrast, such as comparing two clinically relevant covariate values, and asks what the fitted model predicts for exposure or another decision-relevant quantity at the same regimen. The contrast and outcome should be stated explicitly: for example, the predicted exposure ratio for a patient in one covariate group versus a reference group at a specified dose.
If the model expresses a parameter ratio as \(\exp(\delta)\), the corresponding ratio interval is obtained by transforming both endpoints of the interval for \(\delta\). Since the exponential function is increasing, the endpoint order is preserved. If exposure is inversely proportional to that parameter under the specified model and regimen, the exposure ratio is \(\exp(-\delta)\), so the endpoints reverse when transformed from the original interval. These translations are valid only when the stated model relationship applies to the outcome and contrast being discussed.
Worked Example: A Precise Effect With Modest Exposure Consequences
Hypothetical data. Suppose a fitted model estimates a clearance ratio for a 10 kg covariate contrast through \(\delta=\log(\text{clearance ratio})\). The estimate is \(\hat{\delta}=0.07696\), with \(SE(\hat{\delta})=0.025\). For this illustration, assume the model is adequately fitted, the contrast is within the observed covariate range, and the estimate is sufficiently close to normal for a Wald interval and test to be reasonable. Suppose also that, under the specified regimen, predicted exposure is inversely proportional to clearance.
The 95% interval on the log-ratio scale is
The clearance ratio estimate is \(\exp(0.07696)=1.080\), with interval \([\exp(0.02796),\exp(0.12596)]=[1.028,\ 1.134]\). The Wald statistic is \(z=0.07696/0.025=3.078\), giving a two-sided p-value of about 0.0021. Under the model and test approximation, the data provide evidence against a zero effect for this contrast.
But the exposure ratio is the reciprocal clearance ratio. Its estimate is \(\exp(-0.07696)=0.9260\). Transforming the interval gives \([\exp(-0.12596),\exp(-0.02796)]=[0.8817,\ 0.9724]\). Thus the estimated exposure is about 7.4% lower across this contrast, and the interval corresponds to about 2.8% to 11.8% lower exposure.
If, solely for this hypothetical decision, a change of 20% in exposure were the prespecified threshold for a potentially relevant effect, this interval would not reach that threshold. The effect is statistically distinguishable from zero, but its estimated exposure consequence is modest relative to that threshold. This does not establish that the covariate is irrelevant for every regimen or outcome; it means the stated contrast does not imply a 20% exposure change according to this model.
When a Nonsignificant Result Still Needs Attention
A large p-value can result from a small estimated effect, substantial uncertainty, or both. These situations have different implications. When the interval is narrow and excludes effects large enough to matter, the data may be informative against a clinically important effect. When the interval is wide, the data may simply be inconclusive. In the latter case, failure to reject a zero-effect null is not evidence that the effect is negligible.
Worked Example: An Uncertain Estimate With a Potentially Important Consequence
Hypothetical data. For a specified contrast between covariate values, suppose the fitted model estimates a log clearance ratio of \(\hat{\delta}=-0.18\), with \(SE(\hat{\delta})=0.12\). Assume the contrast is supported by the data, the model fit is adequate, and the normal approximation is reasonable. Under the stated regimen, suppose exposure is inversely proportional to clearance.
The 95% interval is
The test statistic is \(z=-0.18/0.12=-1.50\), with two-sided p-value about 0.134. The estimated clearance ratio is \(\exp(-0.18)=0.8353\), with interval \([\exp(-0.4152),\exp(0.0552)]=[0.6603,\ 1.0568]\). The interval includes a clearance ratio of 1, so the estimate is not statistically significant at the 0.05 level under this test.
The exposure ratio is the reciprocal: \(\exp(0.18)=1.197\), or an estimated 19.7% higher exposure. Its interval is \([\exp(-0.0552),\exp(0.4152)]=[0.9463,\ 1.515]\), corresponding to approximately 5.4% lower to 51.5% higher exposure. If a 25% exposure increase were a relevant threshold in this hypothetical setting, the interval includes increases greater than that threshold. The point estimate is below it, but the uncertainty is too large to rule out a potentially relevant increase. The appropriate conclusion is inconclusive about that level of impact—not “no effect.”
Use Clinical Thresholds to Interpret the Interval
A threshold helps make the question concrete: does the interval include effects large enough to alter a decision? It should come from clinical or pharmacological reasoning relevant to the treatment, outcome, and intended use of the model. There is no universal percentage change in exposure that defines importance. The same predicted exposure shift could be inconsequential for one drug and consequential for another, depending on exposure-response relationships, therapeutic range, and available monitoring or dose adjustment.
Worked Example: A Nonsignificant Effect With a Bounded Exposure Range
Hypothetical data. Suppose a model directly gives the log predicted exposure ratio for a prespecified covariate contrast: \(\hat{\delta}=0.02956\), with \(SE(\hat{\delta})=0.04\). Assume the model is adequately fitted, the contrast is supported by observed data, and the Wald approximation is reasonable. For this illustration, define a potentially important effect as an exposure ratio outside the range 0.80 to 1.20, a hypothetical threshold rather than a general clinical rule.
The 95% interval on the log scale is
The test statistic is \(z=0.02956/0.04=0.739\), with a two-sided p-value of about 0.460. The estimated exposure ratio is \(\exp(0.02956)=1.030\), and the transformed interval is \([\exp(-0.04884),\exp(0.10796)]=[0.9523,\ 1.114]\). Thus the estimated exposure is 3.0% higher, with an interval from about 4.8% lower to 11.4% higher.
The interval lies inside the hypothetical range 0.80 to 1.20. Although this result does not establish that the effect is exactly zero, it is more informative about the specified clinical threshold than the p-value alone: effects exceeding the chosen 20% boundary are not included in this interval. This conclusion is conditional on the model, the contrast, and the adequacy of the interval approximation.
A Practical Interpretation Sequence
A disciplined assessment separates estimation, uncertainty, and consequence. The following sequence keeps these questions distinct and makes the final model-building judgment easier to explain.
State which covariate values are compared and whether the target is a parameter contrast, predicted exposure, or another outcome. Use a contrast that is meaningful and supported by the observed covariate range.
Give the effect estimate, its standard error or interval, and the relevant test result when a test is being used. Do not let a p-value substitute for the estimated magnitude.
Use the fitted model to obtain the corresponding change in exposure or other relevant outcome for the stated regimen. Transform interval endpoints correctly if the relationship is nonlinear or inverse.
Ask whether the estimate and its uncertainty include changes that could alter a decision. State the rationale for the threshold and avoid treating a context-specific value as universal.
Consider the effect’s uncertainty and clinical implications alongside the purpose of the model, fit, stability, and predictive performance. A single significance cutoff is not a complete covariate-selection rule.
Diagnostics, Alternatives, and Limitations
Before interpreting a narrow interval as reassuring, check whether it is credible. In NLME models, warning signs include convergence problems, a poorly determined parameter covariance matrix, a covariate contrast supported by very few subjects, or implausible model predictions at the contrast values. Sparse-subgroup and influence diagnostics can reveal whether an apparent effect depends heavily on a few observations. If the standard error is unreliable or the likelihood is markedly non-quadratic near the estimate, a symmetric Wald interval may be misleading; profile-likelihood or resampling-based uncertainty summaries may be useful alternatives when their assumptions and implementation are appropriate.
These approaches answer related but different questions. A null-hypothesis test assesses evidence against a specified zero-effect null. A confidence interval displays uncertainty in the effect estimate and can be compared with a clinical threshold. Model-based exposure predictions connect the parameter effect to a decision-relevant outcome, while predictive assessment asks how well the model forecasts observations. No one of these replaces the others. In particular, a parameter interval does not automatically include uncertainty from choosing the model, misspecifying the structural model, or extrapolating beyond observed covariate values.
Clinical impact also depends on more than a population-average covariate effect. The relevant exposure contrast may vary by dose, regimen, patient characteristics, and other model components. A population-level effect does not, by itself, establish an individual patient’s exposure or dictate an individual dose. Model retention should therefore be justified in relation to the intended use: a covariate may improve prediction or support an important dosing decision even if a simple test is not decisive, while a precisely estimated but clinically negligible effect may not justify a dosing rule.
Check Your Understanding
Answer each question using the distinction between statistical evidence and clinical impact. Numerical solutions use the same hypothetical assumptions stated in the questions.
- A log exposure-ratio estimate is 0.10 with standard error 0.04. Calculate its 95% Wald interval and test statistic. What does the result establish—and what does it not establish?
- A covariate contrast has an estimated log clearance ratio of \(-0.10\). Under a regimen where exposure is inversely proportional to clearance, what is the estimated exposure ratio?
- An effect is not statistically significant, but its exposure interval includes a 40% increase. Can the effect be dismissed as clinically negligible? Explain.
- A 95% exposure-ratio interval is 0.96 to 1.08, while a context-specific threshold defines ratios below 0.80 or above 1.20 as potentially important. What can be concluded about that threshold, conditional on the model?
Solutions. (1) The interval is \(0.10\pm1.96(0.04)=[0.0216,0.1784]\), and \(z=0.10/0.04=2.50\), with a two-sided p-value of about 0.0124. Under the model and Wald approximation, this is evidence against a zero effect; it does not establish clinical importance without translating the estimate and interval to a relevant outcome and threshold. (2) The exposure ratio is \(\exp(0.10)=1.105\), or about 10.5% higher exposure, under the stated inverse relationship. (3) No. A nonsignificant result whose interval includes a 40% increase remains compatible with a potentially important effect; the result is uncertain, not proof of negligible impact. (4) The entire interval lies within 0.80 to 1.20, so it excludes effects beyond the stated threshold at the interval’s nominal 95% level, conditional on the model and interval procedure. It does not prove the effect is exactly zero or that the threshold applies in other settings.